NEW YORK — GenScript Biotech said Wednesday that it has acquired a license to prime editing technology from the Broad Institute.

纽约——金斯瑞生物科技股份有限公司周三表示，已从布罗德研究所获得先导编辑技术的许可。

Prime editing —

Prime editing —

developed

开发的

by Broad's David Liu and colleagues

由Broad研究所的David Liu及其同事

— involves directly writing new genetic information into a specified DNA site using a catalytically impaired Cas9 fused to an engineered reverse transcriptase and programmed with a prime editing guide RNA. The RNA specifies the target site and encodes the desired edit.

— 涉及使用催化功能受损的Cas9与工程化逆转录酶融合，并通过引导编辑向导RNA编程，直接在指定的DNA位点写入新的遗传信息。该RNA指定了目标位点并编码所需的编辑。

In late 2021, Liu

2021年末，刘

cofounded

共同创立

a company called Prime Medicine

一家名为Prime Medicine的公司

to develop and commercialize the technology for human therapeutic use.

开发并商业化用于人类治疗的技术。

Under the terms of its deal with Broad, GenScript may manufacture and commercialize prime editing components, including nucleases and customized synthetic guides, for use by biopharmaceutical companies in preclinical therapeutic research and development.

根据与Broad达成的协议条款，GenScript可以制造和商业化用于生物医药公司临床前治疗研究和开发的先导编辑组件，包括核酸酶和定制的合成引导物。

Financial and other terms were not disclosed.

财务条款及其他条款尚未披露。